In the preclinical syngeneic mouse tumor model, it has been demonstrated that trastuzumab deruxtecan could sensitize tumors to ICI therapy by the enhanced antitumor immunity, which is activated by the delivered DNA topoisomerase I inhibitor payload (44–46). This evidence concerns the gene TOP1 and neoplasm.